Outcomes evaluated with cardiac MRI
| Full analysis set set (n=169) | P values | |||
| Danegaptide high (n=57) | Danegaptide low (n=60) | Placebo (n=52) | ||
| CMR AAR (%LV) | 35.6±10.8 | 37.4±11.4 | 39.2±13.8 | 0.333 |
| CMR AAR (g) | 54.7±24.3 | 55.4±21.5 | 64.4±40.0 | 0.460 |
| Acute infarct size (%LV) | 21.7±10.6 | 21.2±9.7 | 24.2±13.0 | 0.575 |
| Acute infarct size (g) | 33.5±20.4 | 33.5±20.4 | 33.5±20.4 | 0.416 |
| Final infarct size (%LV) | 14.0±7.1 | 13.7±6.7 | 15.4±7.7 | 0.950 |
| Final infarct size (g) | 19.6±11.4 | 18.6±9.6 | 21.4±15.0 | 0.880 |
| Presence of MVO | 40 (72.7) | 39 (67.2) | 37 (72.5) | 0.638 |
| LVEF 90 days (%) | 53.9±9.5 | 52.7±10.3 | 52.1±10.9 | 0.638 |
| MSI | 63.9±14.9 | 65.6±15.6 | 66.7±11.7 | 0.395 |
| Modified APPROACH score | 26.8±11.0 | 27.7±11.4 | 30.4±11.4 | 0.147 |
| Variant MSI | 42.2±33.9 | 45.4±28.5 | 45.7±33.6 | 0.637 |
Data are presented as mean±SD or n (%).
MSI calculated as: (CMR AAR (g) – final infart size (g))/CMR AAR (g).
Variant MSI calculated as: (modified APPROACH (%) – final infarct size (%))/modified APPROACH (%).
P value derived from the Kruskal-Wallis non-parametric test excluding one extreme outlier.
AAR, area at risk; CMR, cardiac MRI; LV, left ventricle; LVEF, left ventricular ejection fraction; MSI, myocardial salvage index; MVO, Micro Vascular Obstruction.